Advancing Relapsed Immune Thrombocytopenia Treatment with Combination Therapy

Managing relapsed immune thrombocytopenia (ITP) remains a significant challenge in hematology. While thrombopoietin receptor agonists (TPO-RAs) like eltrombopag and hetrombopag are effective second-line options, monotherapy often yields limited sustained results for many patients. Consequently, researchers have sought synergistic combinations to improve clinical outcomes. A recent retrospective analysis published in Hematology evaluated the combination of TPO-RAs and sirolimus as a potential relapsed immune thrombocytopenia treatment. This dual-action approach aims to both stimulate platelet production and modulate the underlying autoimmune response.

The study followed 50 patients with relapsed ITP who received combined therapy. Researchers measured efficacy at multiple intervals to determine the speed and durability of the response. Furthermore, they analyzed various patient subgroups to identify who might benefit most from this novel regimen. Notably, the median time to response was remarkably short, with many patients showing improvement within just seven days of starting the treatment.

Clinical Outcomes and Safety Profile

The results demonstrate that adding sirolimus to TPO-RA therapy significantly enhances the overall response rate (ORR). Specifically, the ORR improved from 61% at week 4 to a substantial 82% by week 12. Mean platelet counts also showed a consistent upward trend throughout the study duration. Researchers observed no statistically significant difference in efficacy when comparing hetrombopag to eltrombopag, suggesting that the benefits of sirolimus apply across the TPO-RA class.

Additionally, the analysis revealed that patients who had been diagnosed with ITP for less than one year were more likely to benefit from this relapsed immune thrombocytopenia treatment (p = 0.003). Similarly, factors such as ANA status or the line of treatment (second-line vs. third-line) did not significantly alter the efficacy. The regimen maintained a manageable safety profile, making it a viable consideration for clinicians managing refractory cases in India where access to multiple lines of therapy can sometimes be restricted.

Frequently Asked Questions

How effective is the combination of TPO-RA and sirolimus?

The study reported an overall response rate of 82% at 12 weeks of treatment. This is significantly higher than the roughly 60% response rate typically seen with TPO-RA monotherapy in similar patient populations.

How quickly can patients expect a response?

Most patients showed a rapid response to the combination therapy. The median time to response recorded in the study was seven days, which is beneficial for patients requiring urgent platelet elevation.

Which patients are most likely to benefit from this regimen?

While most subgroups responded well, the research indicates that patients with a shorter disease duration (less than one year) have a higher likelihood of benefiting from this treatment strategy.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the provider. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Wang D et al. Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia. Hematology. 2026 Dec undefined. doi: 10.1080/16078454.2026.2642515. PMID: 41844533.

Feng Y, et al. Sirolimus as Rescue Therapy for Refractory/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study. Front Med (Lausanne). 2020;7:110. doi: 10.3389/fmed.2020.00110.

Neunert C, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. doi: 10.1182/bloodadvances.2019000966.